The waning of the COVID-19 pandemic was reflected in three FDA decisions issued last week for applications that had been under review long past their user fee goal dates because manufacturing inspections could not be conducted.
Revance Therapeutics, Inc.’s long-acting botulinum toxin Daxxify was approved to improve the appearance of frown lines on 8 September...